Immune Checkpoint Inhibitors Plus Anlotinib Versus Anlotinib Alone as Third-Line Treatment in Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

References

• Qiao M , JiangT, RenS, ZhouC. Combination strategies on the basis of immune checkpoint inhibitors in non–small-cell lung cancer: where do we stand?Clin. Lung Cancer19(1), 1–11 (2018).
   PubMed Web of Science ®Google Scholar
• Melosky B , JuergensR, HirshVet al. Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer. Oncologist25(1), 64–77 (2019).
   PubMed Web of Science ®Google Scholar
• Spagnuolo A , PalazzoloG, SementaC, GridelliC. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opin. Pharmacother.21(4), 491–506 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang Z , ZhaoY, LuFet al. Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Ann. Transl. Med.7(18), 452–452 (2019).
   PubMed Web of Science ®Google Scholar
• Bylicki O , BarazzuttiH, PaleironN, MargeryJ, AssiéJ-B, ChouaïdC. First-line treatment of non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors. Biodrugs33(2), 159–171 (2019).
   PubMed Web of Science ®Google Scholar
• Martinez P , PetersS, StammersT, SoriaJ-C. Immunotherapy for the first-line treatment of patients with metastatic non–small cell lung cancer. Clin. Cancer Res.25(9), 2691–2698 (2019).
   PubMed Web of Science ®Google Scholar
• Chen YM . First-line combination immunotherapy for metastatic non-small cell lung cancer. J. Chin. Med. Assoc.83(5), 433–441 (2020).
   PubMed Web of Science ®Google Scholar
• Hanna NH , TeminS, MastersG. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline update summary. JCO Oncol. Pract.16(8), e844–e848 (2020).
   PubMedGoogle Scholar
• Tabchi S , BlaisN. Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front. Oncol.7, 52 (2017).
   PubMed Web of Science ®Google Scholar
• Qiao M , JiangT, ZhouC. Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. J. Thorac. Dis.10(Suppl. 13), S1534–S1546 (2018).
   PubMedGoogle Scholar
• Reck M , MokTSK, NishioMet al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase 3 trial. Lancet Respir. Med.7(5), 387–401 (2019).
   PubMed Web of Science ®Google Scholar
• Han B , ChuT, ZhongRet al. JCSE01.11 Efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol.14(10), Abstract JCSE01.11 (2019).
   Google Scholar
• Liang H , WangM. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag. Res.11, 7707–7719 (2019).
   PubMed Web of Science ®Google Scholar
• Si X , ZhangL, WangHet al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center Phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer122, 32–37 (2018).
   PubMed Web of Science ®Google Scholar
• Han B , LiK, WangQet al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol.4(11), 1569–1575 (2018).
   PubMed Web of Science ®Google Scholar
• Si X , ZhangL, WangHet al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac. Cancer10(3), 551–556 (2019).
   PubMed Web of Science ®Google Scholar
• Tiako Meyo M , JouinotA, Giroux-LeprieurEet al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case–control study. Cancers (Basel)12(2), 473 (2020).
   PubMed Web of Science ®Google Scholar
• Doroshow DB , SanmamedMF, HastingsKet al. Immunotherapy in non–small cell lung cancer: facts and hopes. Clin. Cancer Res.25(15), 4592–4602 (2019).
   PubMed Web of Science ®Google Scholar
• Pirker R . Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr. Opin. Oncol.31(1), 24–28 (2019).
   PubMed Web of Science ®Google Scholar
• Wang Q , GaoJ, DiW, WuX. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunol. Immunother.69(9), 1781–1799 (2020).
   PubMed Web of Science ®Google Scholar
• Guo F , CuiJ. Anti-angiogenesis: opening a new window for immunotherapy. Life Sci.258, 118163 (2020).
   PubMed Web of Science ®Google Scholar
• Yi M , JiaoD, QinS, ChuQ, WuK, LiA. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer18(1), 60 (2019).
   PubMedGoogle Scholar
• Crinò L , BronteG, BidoliPet al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer129, 35–40 (2019).
   PubMed Web of Science ®Google Scholar
• Goldberg SB , GettingerSN, MahajanAet al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, Phase 2 trial. Lancet Oncol.17(7), 976–983 (2016).
   PubMed Web of Science ®Google Scholar
• Goldberg SB , SchalperKA, GettingerSNet al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, Phase 2 trial. Lancet Oncol.21(5), 655–663 (2020).
   PubMed Web of Science ®Google Scholar
• Frega S , BonannoL, GuarneriV, ConteP, PaselloG. Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): towards a less dismal future?Crit. Rev. Oncol. Hematol.128, 19–29 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Z , YangJ-J, TuH-Y, YanH-H, WuY-L. Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. Int. J. Clin. Oncol.25(2), 267–273 (2019).
   PubMed Web of Science ®Google Scholar
• Masuda C , SugimotoM, WakitaDet al. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clin. Exp. Metastasis37(1), 199–207 (2019).
   PubMed Web of Science ®Google Scholar
• Jiang S , LiangH, LiuZet al. The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a Phase III randomized control trial (ALTER0303). Oncologist25(5), e870–e874 (2020).
   PubMed Web of Science ®Google Scholar